EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety Signals of CRS and ICANS With Tarlatamab in Relapsed Small Cell Lung Cancer: Insights From a Small Case Study

Juwhan Choi iD, Seunghun Lee iD, Sung Yong Lee iD

Thoracic Cancer · 2026

DOI: 10.1111/1759-7714.70389 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2026. Verfasst von Juwhan Choi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy, and Critical Care Medicine Department of Internal Medicine Korea, University Guro Hospital Korea University College o…. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Cytokine Release Syndrome, Neoplasm Recurrence, Local. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tarlatamab, a delta‐like ligand 3‐targeted bispecific T‐cell engager, has shown activity in previously treated small cell lung cancer (SCLC); however, real‐world data on cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) remain limited. We evaluated the efficacy and safety of tarlatamab and laboratory findings associated with CRS in patients previously treated for extensive‐stage SCLC. Materials and Methods We retrospectively analyzed 11 patients who received tarlatamab through an expanded access program between October 2024 and May 2026. Repeated laboratory measurements were analyzed using generalized estimating equations and mixed‐effects models.

Results

The objective response and disease control rates were 54.5% and 72.7%, respectively. The mean and median tumor size changes from baseline were −9.1% and −25.0%, respectively. The median progression‐free survival and overall survival were 3.8 months (95% confidence interval [CI]: 1.9–not reached) and 10.1 months (95% CI: 4.5–not reached), respectively. CRS occurred in seven patients (63.6%), with 10 events, all occurring during the first cycle and limited to Grade 1 or 2. No CRS event required tocilizumab treatment, intensive care unit admission, dose reduction, or treatment discontinuation. One patient developed Grade 3 ICANS and recovered fully. CRS events were associated with higher neutrophil percentages, lower lymphocyte percentages, and higher neutrophil‐to‐lymphocyte ratios than no‐CRS events.

Conclusion

Tarlatamab shows encouraging antitumor activity and manageable toxicity in heavily pretreated Korean patients with SCLC. The neutrophil‐to‐lymphocyte ratio may represent an exploratory, concurrent hematologic correlate of CRS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsCytokine Release SyndromeNeoplasm Recurrence, LocalNeurotoxicity SyndromesHumansFemaleMaleAgedRetrospective StudiesMiddle AgedAntibodies, Bispecific

Stichwörter der Autor:innen

cytokine release syndromedelta‐like ligand 3immune effector cell‐associated neurotoxicity syndromesmall cell lung cancer

Substanzen

AMG 757Antibodies, Bispecific

Autor:innen und Institutionen

  • Division of Pulmonary, Allergy, and Critical Care Medicine Department of Internal Medicine Korea, University Guro Hospital Korea University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Juwhan Choi, Seunghun Lee, Sung Yong Lee

Zitieren

APA

Choi, J., Lee, S., & Lee, S. Y. (2026). Safety Signals of CRS and ICANS With Tarlatamab in Relapsed Small Cell Lung Cancer: Insights From a Small Case Study. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70389

Vancouver

Choi J, Lee S, Lee SY. Safety Signals of CRS and ICANS With Tarlatamab in Relapsed Small Cell Lung Cancer: Insights From a Small Case Study. Thoracic Cancer. 2026. doi:10.1111/1759-7714.70389

BibTeX
@article{Choi2026,
  author = {Choi, Juwhan and Lee, Seunghun and Lee, Sung Yong},
  title = {Safety Signals of CRS and ICANS With Tarlatamab in Relapsed Small Cell Lung Cancer: Insights From a Small Case Study},
  journal = {Thoracic Cancer},
  year = {2026},
  doi = {10.1111/1759-7714.70389}
}
Kostenlos starten →